Lipa

(redirected from Lysosomal Acid Lipase)
Also found in: Dictionary, Medical, Acronyms.

Lipa

A subdivision of the Croatian kuna. A lipa is equal in value to 1/100 of a kuna. See also: Cent.

References in periodicals archive ?

Rapid progression and mortality of lysosomal acid lipase deficiency presenting in infants.

Launch of New Lysosomal Acid Lipase Deficiency Educational Resource on epgonline.org

The Center for Veterinary Medicine (CVM) approved an application for a recombinant DNA (rDNA) construct in chickens that are genetically engineered (GE) to produce a recombinant form of human lysosomal acid lipase (rhLAL) protein in their egg whites.

United States : FDA approves first drug to treat a rare enzyme disorder in pediatric and adult patients

The differential diagnosis of nontraumatic splenomegaly with hypertriglyceridemia includes: hereditary absence of lipoprotein lipase or apoC-11, rare apoE3 mutations, deficiency of lysosomal acid lipase, or hemophagocytic lymphohistiocytosis (1-3).

An unusual case of severe hypertriglyceridemia and splenomegaly

Synageva) (NASDAQ:GEVA), a clinical stage biopharmaceutical company developing therapeutic products for rare diseases, today announced that the first patient initiated treatment in the ARISE trial (Acid Lipase Replacement Investigating Safety and Efficacy), a global, Phase 3, randomized, double-blind, placebo-controlled study of sebelipase alfa in children and adults with late onset lysosomal acid lipase deficiency (LAL Deficiency).

Synageva BioPharma[TM] Initiates Dosing in Phase 3 Trial of Sebelipase Alfa in Children and Adults with Late Onset LAL Deficiency

In addition, the company's metabolic franchise includes two enzyme replacement therapies for patients with life-threatening and ultra-rare disorders, hypophosphatasia and lysosomal acid lipase deficiency (LAL-D).

Alexion, NICE, NHS England Reach Funding Agreement for Strensiq (asfotase alfa) for Pediatric-onset Hypophosphatasia

Synageva) (NASDAQ:GEVA), a clinical stage biopharmaceutical company developing therapeutic products for rare diseases, today announced publication of the 12-week Phase I/II extension study data of sebelipase alfa in adults with lysosomal acid lipase deficiency (LAL Deficiency) in the online version and an upcoming print edition of Hepatology.

Hepatology Publishes 12-Week Phase I/II Extension Study Data of Sebelipase Alfa in Adults with Late Onset LAL Deficiency

Manisha Balwani will present 38-week data from the Phase I/II extension study of sebelipase alfa in adults with late onset lysosomal acid lipase deficiency (LAL Deficiency).

Synageva BioPharma[TM] Highlights Data Presentations at the 9th Annual Lysosomal Disease Network (LDN) WORLD Symposium

Sebelipase alfa (formerly referred to as SBC-102) is a recombinant form of the human LAL enzyme being developed as an enzyme replacement therapy for Lysosomal Acid Lipase (LAL) Deficiency, a lysosomal storage disorder (LSD).

Synageva BioPharma Announces Closing of Public Offering and Exercise of Option to Purchase Additional Shares

LAL Deficiency (Lysosomal Acid Lipase Deficiency) is reportedly a rare, autosomal recessive lysosomal storage disorder (LSD) that is caused by a marked decrease in lysosomal acid lipase activity.

Synageva BioPharma presents positive interim data at eighth annual Lysosomal Disease Network (LDN) World Symposium

Synageva") (NASDAQ:GEVA), a clinical stage biopharmaceutical company developing therapeutic products for rare diseases, today announced six month results from an ongoing extension study of sebelipase alfa in adults with late onset Lysosomal Acid Lipase (LAL) Deficiency at the American Association for the Study of Liver Diseases (AASLD) annual meeting being held in Boston, MA, November 9-13, 2012.

Synageva BioPharma[TM] Announces Six-Month Data from Extension Study of SBC-102 (sebelipase alfa) in Late Onset LAL Deficiency at the AASLD Annual Meeting

The company's lead candidate SBC-102 is being developed as an enzyme replacement therapy for Lysosomal Acid Lipase (LAL) Deficiency.